Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Influenza Clinical Trial

Official title:

Clinical Study Protocol Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011， in Infants Aged Between 6-12months Old

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01355172
• Other study ID #: FLU10T11C
• Status: Completed
• Phase: Phase 4
• First received: May 15, 2011
• Last updated: July 12, 2012
• Start date: November 2010

Study information

• Verified date: July 2012
• Source: Adimmune Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan : Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the seasonal flu vaccine(AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks after two doses of study vaccine, 4 weeks apart, in infants between 6 and 12 months of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. primary completion date: September 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 6 Months to 1 Year

Eligibility

Inclusion Criteria:

• Boys or girls and aged >= 6 months old to <= 12 months old on the day of first vaccination;

• Subject's parent(s) or legal guardian(s) must be willing to comply with planned study procedures and be available for all study visits;

• Subject must be in good physical health on the basis of medical history, physical examination;

• Subject's parent(s) or legal guardian(s) must read and signed the study-specific informed consent prior to initiation of any study procedure.

Exclusion Criteria:

• Subjects had received influenza vaccine;

• History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication;

• Personal or family history of Guillain- Barre' Syndrome;

• An acute febrile illness within 1 week prior to vaccination;

• Current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours;

• Subjects with influenza-like illness as defined by the presence of fever (temperature >= 38'C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;

• Immunodeficiency, immunosuppressive or significant chronic illness not suitable for inactivated influenza vaccination;

• History of wheezing or bronchodilator use within 3 months prior to study vaccine;

• Receipt of live virus vaccine within 1 month prior to study vaccine or expected receipt vaccination before the last blood sampling for immunogenicity evaluation;

• Receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected receipt vaccination before the last blood sampling for immunogenicity evaluation;

• Receipt of any blood products, including immunoglobulin in the prior 3 months;

• Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• AdimFlu-S
0.25mL per injection 2 injections at 4 weeks apart

Locations

Country	Name	City	State
Taiwan	China Medicine University Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
Adimmune Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HA antibody titers will be determined using the WHO HAI reference technique.		Serum samples will be obtained prior to vaccination (baseline), and 4 weeks after each vaccination.	No
Secondary	The secondary objective is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S manufactured by Adimmune Corporation.	Safety data will consist of reactogenicity, serious and non-serious adverse events. Reactogenicity events are pre-specified adverse events systematically recorded for 7 days after each vaccination.; The events included fever (=38.0°C), runny nose or nasal congestion, cough, sore throat, muscle aches, headache, vomiting, nausea and malaise. Furthermore, the local (injection site) reactions were also evaluated, including soreness/pain, swelling, redness, ecchymosis and limitation of arm motion.	(4 weeks after two doses of study vaccine, 4 weeks apart), Physical examination will be performed at each visit. Reactogenicity will be recorded for 7 days after each vaccination.	Yes